Expanding the Diversity of Allosteric Bcr-Abl Inhibitors

[Image: see text] Inhibition of Bcr-Abl kinase activity by imatinib for the treatment of chronic myeloid leukemia (CML) currently serves as the paradigm for targeting dominant oncogenes with small molecules. We recently reported the discovery of GNF-2 (1) and GNF-5 (2) as selective non-ATP competiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Xianming, Okram, Barun, Ding, Qiang, Zhang, Jianming, Choi, Yongmun, Adrián, Francisco J., Wojciechowski, Amy, Zhang, Guobao, Che, Jianwei, Bursulaya, Badry, Cowan-Jacob, Sandra W., Rummel, Gabriele, Sim, Taebo, Gray, Nathanael S.
Formato: Texto
Lenguaje:English
Publicado: American Chemical Society 2010
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951064/
https://www.ncbi.nlm.nih.gov/pubmed/20828158
http://dx.doi.org/10.1021/jm100555f

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951064/
https://www.ncbi.nlm.nih.gov/pubmed/20828158
http://dx.doi.org/10.1021/jm100555f

Ejemplares similares